Skip navigation

AstraZeneca, one of the world's largest pharmaceuticals companies, and
IBM, the world's largest information technology company, today announced
that they had signed a global strategic outsourcing agreement worth $1.7
billion over seven years. The agreement, covering the provision of IT
infrastructure services to 45 countries, is the largest of its kind in the
pharmaceutical industry.

Under this agreement, IBM will provide a range of IT services to
AstraZeneca throughout its global organisation. These cover PC
management, network and communications services, including e-Mail, and
computer operations support. AstraZeneca will retain control of its IT
technical strategy and the development and support of its application
systems.

Paul Burfitt, Chief Information Officer of AstraZeneca, said, "Our
partnership with IBM will enable AstraZeneca to concentrate the effort of
its Information Services (IS) capabilities on such strategic opportunities
as e-business and informatics in R&D, and to further encourage added value
from IS activities. This partnership will give AstraZeneca access to
greater expertise and resource world-wide and will enhance competitive
edge. It will also provide additional career and personal development
opportunities for IT professionals joining IBM."

Frank Kern, General Manager, Professional Services, IBM Global Services,
said, "This alliance joins two world class players. Our combined
strengths, global reach and culture will enable AstraZenenca to optimise
its global IT infrastructure and create business value. IBM will
contribute its proven skills and expertise in leveraging technology. This
will ensure a robust IT infrastructure to support AstraZeneca's fast
moving business, allowing the organisation to focus on strategic IS
opportunities."

Up to 1200 AstraZeneca staff currently involved in the provision of IT
services, principally from the US, UK and Sweden, will transfer to IBM.
No redundancies are anticipated.


Ref No: 00/021

Notes to the Editor:

ABOUT ASTRAZENECA

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of ethical (prescription)
pharmaceuticals and the supply of healthcare services. It is one of the
top five pharmaceutical companies in the world with healthcare sales of
over $15 billion and leading positions in sales of gastrointestinal,
oncology, anaesthesia including pain management, cardiovascular, central
nervous system (CNS) and respiratory products.

ABOUT IBM

IBM Global Services is the world's largest information technology services
provider, with 2000 revenues of more than $33 billion. Services is the
fastest growing part of IBM, with more than 148,000 professionals serving
customers in 160 countries. IBM Global Services integrates IBM's broad
range of capabilities - services, hardware, software and research to help
companies of all sizes realise the full value of information technology.
For more information visit http://www.ibm.com/services


IBM Life Sciences brings together IBM resources, from research and
e-business expertise to data and storage management and high-performance
computing, to offer new solutions for the life sciences market, including
biotechnology, genomic, e-health, pharmaceutical, and agri-science
industries.

For further information:

Bill Mew

IBM Global Services

Tel: 44 (0)20 72025769

E-mail: mewb@uk.ibm.com


Or

Emma Thompson / Nicky Morgan

On behalf of IBM

Tel: 01753 790700

Email: ethompson@uk.brodeur.com


nmorgan@uk.brodeur.com

This press release was distributed by ResponseSource Press Release Wire on behalf of Pleon in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.